New drug SY-9453 targets Hard-to-Treat cancers in early trial
NCT ID NCT07469982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a new oral drug, SY-9453, in 122 adults with advanced solid tumors that have a specific genetic deletion (MTAP). The main goals are to check safety, find the best dose, and get a first look at whether the drug can shrink tumors. Participants must have tried standard treatments without success or have no standard options left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SY-9453 capsules
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors that have a specific genetic deletion (MTAP).
- What could go wrong
- This is an early Phase 1 trial with only 122 participants, focused on safety and dosing. It is too soon to know if SY-9453 will be effective or have manageable side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS WITH HOMOZYGOUS MTAP DELETION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, China